The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Suramin: an anticancer drug with a unique mechanism of action.
Abstract
We administered suramin, an anti-parasitic drug and reverse transcriptase inhibitor, to 15 patients with metastatic cancer. This compound is known to inhibit the binding of growth factors (eg, epidermal growth factor [EGF], platelet-derived growth factor [PDGF], tumor growth factor-beta [TGF-beta]) to their receptors and thus antagonize the ability of these factors to stimulate growth of tumor cells in vitro. There were no complete responses (CRs), four partial responses (PRs) (two of ten adrenal cortex, one of four renal, one of one adult T-cell leukemia-lymphoma [HTLV-1]), and two minimal responses (MRs) (two of ten adrenal cortex). Toxicity included proteinuria (14 patients), reversible liver function test abnormalities (eight), vortex keratopathy (five), adrenal insufficiency (three), coagulopathy secondary to increased circulating levels of glycosaminoglycans (11), and one case of a reversible acute demyelinating polyneuropathy resembling the Guillain-Barrè syndrome. We conclude that suramin is an active agent in the treatment of metastatic cancer, and further work is necessary to define its scope.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heparan sulphate bound growth factors: a mechanism for stromal cell mediated haemopoiesis
Roberts, R., Gallagher, J., Spooncer, E., Alien, T. D., Bloomfield, F., & Dexter, T. M. (1988) · Nature · doi:10.1038/332376a0 · Cited by 807
Gordon, M. Y., Riley, G. P., Watt, S. M., & Greaves, M. F. (1987) · Nature · doi:10.1038/326403a0 · Cited by 604
Suramin Protection of T Cells in Vitro Against Infectivity and Cytopathic Effect of HTLV-III
Mitsuya, H., Popovic, M., Yarchoan, R., Matsushita, S., Gallo, R. C., & Broder, S. (1984) · Science · doi:10.1126/science.6091268 · Cited by 397
Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cells
Coffey, R. J., Leof, E. B., Shipley, G. D., & Moses, H. L. (1987) · Journal of Cellular Physiology · doi:10.1002/jcp.1041320120 · Cited by 379
Betsholtz, C., Johnsson, A., Heldin, C. H., & Westermark, B. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.17.6440 · Cited by 264
Proteoglycans: structure, function, and role in neoplasia.
Iozzo, R. V. (1985) · PubMed · Cited by 190
Transport of heparan sulfate into the nuclei of hepatocytes.
Ishihara, M., Fedarko, N. S., & Conrad, H. E. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67058-9 · Cited by 188
Heparin sequences in the heparan sulfate chains of an endothelial cell proteoglycan.
Nader, H. B., Dietrich, C. P., Buonassisi, V, & Colburn, P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.11.3565 · Cited by 163
Garrett, J. S., Coughlin, S. R., Niman, H. L., Tremble, P., Giels, G. M., & Williams, L. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.23.7466 · Cited by 155
Fujita, M., Spray, D. C., Choi, H., Sáez, J. C., Watanabe, T., Lc, R., Hertzberg, E. L., & Reid, L. M. (1987) · Hepatology · doi:10.1002/hep.1840070702 · Cited by 105
Antiproliferative effects of suramin on lymphoid cells.
Spigelman, Z. S., Dowers, A., Kennedy, S., et al. (1987) · PubMed · Cited by 88
Circulating glycosaminoglycan anticoagulants associated with suramin treatment.
Horne, M. K., Stein, C. A., LaRocca, R. V., & Myers, C. E. (1988) · Blood · doi:10.1182/blood.v71.2.273.273 · Cited by 79
Self-citationConstantopoulos, G., Rees, S. M., Cragg, B. G., Barranger, J. A., & Brady, R. O. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.6.3700 · Cited by 77
Quantification of Suramin by Reverse-Phase Ion-Pairing High-Performance Liquid Chromatography
Klecker, R. W., & Collins, J. M. (1985) · Journal of Liquid Chromatography · doi:10.1080/01483918508074087 · Cited by 43
Cited by
Bowne, W. B., Lewis, J. J., Filippa, D. A., Niesvizky, R., Brooks, A. D., Burt, M. E., & Brennan, M. F. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990201)85:3<706::aid-cncr21>3.0.co;2-7 · Cited by 411
Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L., & Stein, C. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.6.2620 · Cited by 326
Self-citationDredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296
Crucitti, F., Bellantone, R., Ferrante, A., Boscherini, M., & Crucitti, P. (1996) · Surgery · doi:10.1016/s0039-6060(96)80164-4 · Cited by 247
Versatile synthetic alternatives to Matrigel for vascular toxicity screening and stem cell expansion
Nguyen, E. H., Daly, W. T., Le, N. N. T., Farnoodian, M., Belair, D. G., Schwartz, M. P., Lebakken, C. S., Ananiev, G. E., Saghiri, M. A., Knudsen, T. B., et al. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0096 · Cited by 136
Metadata
- Authors
- Stein, C. A., LaRocca, R. V., Thomas, R., McAtee, N., & Myers, C. E.
- Venue
- Journal of Clinical Oncology
- Published
- 1989-04
- Volume
- 7
- Issue
- 4
- Pages
- 499-508
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2242063705
- Cited by
- 375
- References
- 14
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.